The Company undertakes that the Proceeds will be used to support the costs and expenses related to the development of Dusquetide for the treatment of oral mucositis in head and neck cancer patients and other activities necessary to obtain and maintain the authorizations (“ Marketing Authorizations ”) issued by all applicable regulatory authorities which are necessary for the marketing, use, distribution and sale of the Product, as such term is defined in the License Agreement. Accordingly, the Company undertakes to utilize such Proceeds only for the furtherance of the development of Dusquetide for the treatment of oral mucositis in head and neck cancer patients and other activities necessary to obtain and maintain the Marketing Authorizations in the Territory, as defined in the License Agreement. The Company shall send to the Purchaser bi-annual reports showing the proper allocation of the Proceeds received.